These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26178150)

  • 21. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
    Kusunoki H; Taniyama Y; Rakugi H; Morishita R
    J Am Heart Assoc; 2013 Apr; 2(2):e000103. PubMed ID: 23608606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia.
    Kim HS; Kim H; Lee SH; Kim JH
    J Clin Pharm Ther; 2020 Dec; 45(6):1264-1270. PubMed ID: 32737930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irbesartan substitution for valsartan or losartan in treating hypertension.
    Graham MR; Allcock NM
    Ann Pharmacother; 2002 Dec; 36(12):1840-4. PubMed ID: 12452741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan].
    Ariyoshi Y; Mizumoto K
    Nihon Yakurigaku Zasshi; 2009 May; 133(5):275-80. PubMed ID: 19443965
    [No Abstract]   [Full Text] [Related]  

  • 28. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced platelet release of superoxide anion in systemic hypertension: role of AT1 receptors.
    Germanò G; Sanguigni V; Pignatelli P; Caccese D; Lenti L; Ragazzo M; Lauro R; Violi F
    J Hypertens; 2004 Jun; 22(6):1151-6. PubMed ID: 15167450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
    Nussberger J; Aubert JF; Bouzourene K; Pellegrin M; Hayoz D; Mazzolai L
    Hypertension; 2008 May; 51(5):1306-11. PubMed ID: 18391092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients.
    Hamada T; Mizuta E; Kondo T; Hirai M; Yamada K; Kato M; Shigemasa C; Yamamoto Y; Ninomiya H; Igawa O; Hisatome I
    Arzneimittelforschung; 2010; 60(2):71-5. PubMed ID: 20329654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.
    Schievink B; de Zeeuw D; Parving HH; Rossing P; Lambers Heerspink HJ
    Br J Clin Pharmacol; 2015 Oct; 80(4):678-86. PubMed ID: 25872610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Irbesartan--antihypertensive treatment in patients with heart failure and diabetes mellitus].
    Zukowska-Szczechowska E; Gosek K; Grzeszczak W
    Przegl Lek; 2002; 59(3):160-4. PubMed ID: 12184030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.
    Anjaneyulu M; Chopra K
    Am J Nephrol; 2004; 24(5):488-96. PubMed ID: 15353911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effects of quinapril and irbesartan on P-wave dispersion in hypertensive patients.
    Guntekin U; Gunes Y; Tuncer M; Simsek H; Gunes A
    Adv Ther; 2008 Aug; 25(8):775-86. PubMed ID: 18670740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure.
    Watanabe R; Suzuki J; Wakayama K; Kumagai H; Ikeda Y; Akazawa H; Komuro I; Isobe M
    Hypertens Res; 2016 Apr; 39(4):237-44. PubMed ID: 26657004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients.
    Masaki M; Komamura K; Goda A; Hirotani S; Otsuka M; Nakabo A; Fukui M; Fujiwara S; Sugahara M; Lee-Kawabata M; Tsujino T; Koshiba M; Masuyama T
    J Cardiol; 2014 Mar; 63(3):205-10. PubMed ID: 24060523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.
    De Luis DA; Conde R; Gonzalez Sagrado M; Aller R; Izaola O; Perez Castrillon JL; Romero E; Castro MJ
    Eur Rev Med Pharmacol Sci; 2010 Sep; 14(9):759-63. PubMed ID: 21061834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
    Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
    Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.